ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Ar...
ProUroCare Medical reported revenue of $0 for fiscal year 2012, and net income of -$2.96 million. In Q3 2013 (the quarter ended September 30, 2013) revenue was $0. Its market capitalization was $1,860 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2012; market data as of October 8, 2026.
No profile data available.